Pacira Pharmaceuticals (PCRX) Stock Statistics & Valuation Metrics

Pacira Pharmaceuticals has a market cap or net worth of $1.11B. The enterprise value is $1.27B.

Pacira Pharmaceuticals has 44,932,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacira Pharmaceuticals’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -7.96%.

The current PE Ratio of Pacira Pharmaceuticals is ―. Pacira Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Pacira Pharmaceuticals had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.

In the last 12 months, operating cash flow was 134.52M and capital expenditures -17.45M, giving a free cash flow of 117.07M billion.

Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Pacira Pharmaceuticals upcoming earnings date is Oct 30, 2025, Before Open (Confirmed).

Pacira Pharmaceuticals as a current ratio of 2.40, with Debt / Equity ratio of 83.32%

In the past 12 months, Pacira Pharmaceuticals has paid 36.45M in taxes.

Pacira Pharmaceuticals EV to EBITDA ratio is 42.36, with an EV/FCF ratio of 6.90.

Pacira Pharmaceuticals has $445.86M in cash and marketable securities with $631.40M in debt, giving a net cash position of $185.54M billion.

Gross margin is 78.19%, with operating margin of -10.47%, and net profit margin of -14.20%.

The average price target for Pacira Pharmaceuticals is $27.00, which is 11.43% higher than the current price. The consensus rating is Hold